Protagonist Therapeutics (PTGX) CEO sells shares after exercising stock options

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Protagonist Therapeutics President and CEO Dinesh V. Patel reported multiple stock transactions in January 2026. On January 23, 2026, he made a charitable donation of 6,000 shares of common stock to a donor-advised fund for charitable purposes.

Across January 23–27, 2026, he exercised vested stock options to acquire common shares at exercise prices of $4.21 and $21.58 per share and sold matching share amounts in open-market transactions at reported weighted average sale prices of $84.59, $84, $84.05 and $83.19 per share.

Following these transactions, he directly owned 574,505 shares of common stock and held 300,000 stock options with exercise price $21.58 expiring on October 11, 2026 and 10,685 stock options with exercise price $4.21 expiring on April 29, 2026.

Insider Trade Summary

Net Seller: 48,273 shares ($4,063,743)

Net Sell 13 txns

Insider PATEL DINESH V PH D

Role President and CEO

Sold 48,273 shs ($4.06M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	4,068	$0.00	--
Exercise	Common Stock	4,068	$21.58	$88K
Sale	Common Stock	4,068	$83.19	$338K
Exercise	Stock Option (right to buy)	10,685	$0.00	--
Exercise	Stock Option (right to buy)	14,205	$0.00	--
Exercise	Common Stock	10,685	$4.21	$45K
Sale	Common Stock	10,685	$84.00	$898K
Exercise	Common Stock	14,205	$21.58	$307K
Sale	Common Stock	14,205	$84.05	$1.19M
Exercise	Stock Option (right to buy)	19,315	$0.00	--
Gift	Common Stock	6,000	$0.00	--
Exercise	Common Stock	19,315	$4.21	$81K
Sale	Common Stock	19,315	$84.59	$1.63M

Holdings After Transaction: Stock Option (right to buy) — 300,000 shares (Direct); Common Stock — 578,573 shares (Direct)

Footnotes (1)

On January 23, 2026, the Reporting Person made a charitable donation of 6,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84.41 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.095. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.075. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.06 to $83.59. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. These stock options are fully vested and will expire on April 29, 2026. These stock options are fully vested and will expire on October 11, 2026.

Form 4 Insider Transactions: What Each Field Means →

01/27/2026 - 09:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATEL DINESH V PH D

(Last)

(First)

(Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK

94560-1160

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
01/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/23/2026		G⁽¹⁾		6,000	D	$0.00	574,505	D
Common Stock	01/23/2026		M		19,315	A	$4.21	593,820	D
Common Stock	01/23/2026		S		19,315	D	$84.59⁽²⁾	574,505	D
Common Stock	01/26/2026		M		10,685	A	$4.21	585,190	D
Common Stock	01/26/2026		S		10,685	D	$84⁽³⁾	574,505	D
Common Stock	01/26/2026		M		14,205	A	$21.58	588,710	D
Common Stock	01/26/2026		S		14,205	D	$84.05⁽⁴⁾	574,505	D
Common Stock	01/27/2026		M		4,068	A	$21.58	578,573	D
Common Stock	01/27/2026		S		4,068	D	$83.19⁽⁵⁾	574,505	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$4.21	01/23/2026		M			19,315	⁽⁶⁾	04/29/2026	Common Stock	19,315	$0.00	10,685	D
Stock Option (right to buy)	$4.21	01/26/2026		M			10,685	⁽⁶⁾	04/29/2026	Common Stock	10,685	$0.00	0	D
Stock Option (right to buy)	$21.58	01/26/2026		M			14,205	⁽⁷⁾	10/11/2026	Common Stock	14,205	$0.00	304,068	D
Stock Option (right to buy)	$21.58	01/27/2026		M			4,068	⁽⁷⁾	10/11/2026	Common Stock	4,068	$0.00	300,000	D

Explanation of Responses:

1. On January 23, 2026, the Reporting Person made a charitable donation of 6,000 shares of common stock to a donor-advised fund, which will use the gifted shares for charitable purposes.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84.41 to $84.64. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.095. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

4. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $84 to $84.075. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

5. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $83.06 to $83.59. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

6. These stock options are fully vested and will expire on April 29, 2026.

7. These stock options are fully vested and will expire on October 11, 2026.

	/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did PTGX CEO Dinesh V. Patel report on this Form 4?

Dinesh V. Patel reported option exercises and related share sales, plus a charitable gift. He exercised vested stock options at $4.21 and $21.58 and sold equivalent share amounts at weighted average prices between $83.19 and $84.59 per share over January 23–27, 2026.

How many Protagonist Therapeutics (PTGX) shares did the CEO donate to charity?

He donated 6,000 shares of PTGX common stock to a donor-advised fund. The filing states the fund will use the gifted shares for charitable purposes, and this donation reduced his directly held common stock before subsequent option exercises and sales.

At what prices did the PTGX CEO sell common stock in these transactions?

The CEO’s reported sales used weighted average prices of $84.59, $84, $84.05 and $83.19 per share. Each price reflects multiple trades within narrow intraday ranges, with full breakdowns available upon request to the issuer, SEC staff, or a security holder.

What stock options did the PTGX CEO exercise according to this Form 4?

He exercised fully vested stock options with exercise prices of $4.21 and $21.58 per share. These exercises occurred on January 23, 26 and 27, 2026, converting option positions into common shares that were then sold or added to his direct holdings.

How many PTGX common shares does the CEO own after these transactions?

After the reported January 2026 transactions, he directly owned 574,505 shares of PTGX common stock. This figure reflects the impact of the 6,000-share charitable donation, multiple option exercises and the subsequent open-market sales reported on the Form 4.

What PTGX stock options does the CEO continue to hold after the Form 4 trades?

He held 10,685 fully vested stock options at a $4.21 exercise price expiring April 29, 2026, and 300,000 fully vested options at a $21.58 exercise price expiring October 11, 2026. These remaining options provide potential future rights to acquire additional PTGX shares.